Oncolytic Virotherapy Market Size & Growth Forecast 2027–2036, By Segments (Virus Type, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Oncolytic Virotherapy Market size was over USD 37.95 million in 2026 and is likely to grow at a 23.04% CAGR between 2027 and 2036, reaching USD 301.77 million by 2036. The industry revenue for 2027 is estimated at USD 46.21 million.
Get more details on this report
Request Free Sample ReportOncolytic Virotherapy Market Intelligence Snapshot
Regional Market Dynamics
- North America leads because of its advanced oncology ecosystem, strong biopharmaceutical innovation, established clinical research infrastructure, and active cancer immunotherapy development.
- Asia Pacific is projected to expand at a 28.16% CAGR, supported by rising oncology research, expanding healthcare capabilities, greater clinical development participation, and increasing adoption of advanced cancer therapies.
Segment Momentum
- Genetically Engineered Oncolytic viruses are the largest and fastest-growing segment because they offer optimized tumor selectivity, therapeutic payload delivery, and adaptable designs that support evolving oncology treatment strategies.
- Solid Tumors are expanding fastest as development programs broaden virotherapy use beyond traditional indications, creating greater commercial and clinical opportunities across larger patient populations.
Market Expansion Drivers
- Rising global cancer burden increasing demand for advanced targeted gene-based therapies.
- Expanding clinical trials combining oncolytic viruses with immunotherapy accelerating treatment innovation.
- Increasing government and institutional research funding supporting commercialization of virotherapy platforms.
Leading Market Participants
- Major companies in the oncolytic virotherapy market include Amgen Inc. (United States), Takara Bio Inc. (Japan), Transgene SA (France), Shanghai Sunway Biotech Co., Ltd. (China), Pfizer Inc. (United States), Calidi Biotherapeutics, Inc. (United States), Lokon Pharma AB (Sweden), TILT Biotherapeutics Ltd. (Finland), CG Oncology, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 37.95 million
- 2027 Estimated Market Size: USD 46.21 million.
- Projected Market Size: USD 301.77 million by 2036
- Growth Forecast: 23.04% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Genetically Engineered Oncolytic (Virus Type) | Melanoma (Application) | Hospitals (End-use)
- Emerging Opportunity Segment: Genetically Engineered Oncolytic (Virus Type) | Solid Tumors (Application) | Specialty Clinics (End-use)
Market Growth Drivers and Industry Trends
Rising global cancer burden increasing demand for advanced targeted gene-based therapies
The growing prevalence of cancer worldwide is creating a substantial need for treatment approaches capable of selectively targeting malignant cells, supporting the expansion of the oncolytic virotherapy market. Oncolytic viruses are designed to preferentially infect and destroy cancer cells while also stimulating immune responses against tumors, offering a distinct therapeutic mechanism compared with conventional cancer treatments. Increasing recognition of tumor heterogeneity and the limitations associated with existing treatment modalities is encouraging researchers and clinicians to explore gene-based and biologically targeted approaches for cancers that remain difficult to treat with standard therapies.
Expanding clinical trials combining oncolytic viruses with immunotherapy accelerating treatment innovation
Combination treatment strategies are becoming an important area of oncology research, and the oncolytic virotherapy market is benefiting from increasing clinical investigation of oncolytic viruses alongside immunotherapies. Oncolytic viruses can modify the tumor microenvironment and promote immune activation, potentially improving the ability of immune-based therapies to recognize and attack cancer cells. Clinical studies evaluating combinations with immune checkpoint inhibitors and other immunomodulatory approaches are therefore expanding the therapeutic potential of virotherapy platforms while generating evidence on dosing, safety, treatment sequencing, and patient selection.
Increasing government and institutional research funding supporting commercialization of virotherapy platforms
Greater public and institutional investment in cancer research is strengthening the oncolytic virotherapy market by providing financial support for the development, validation, and manufacturing of advanced virotherapy technologies. Research funding can help investigators progress promising viral platforms from laboratory studies through preclinical development and clinical evaluation, while institutional support contributes to research infrastructure and specialized capabilities required for complex biological therapies. Continued funding across areas such as viral engineering, tumor targeting, manufacturing processes, and clinical development can also help address technical barriers associated with bringing oncolytic therapies into broader clinical use.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer burden increasing demand for advanced targeted gene-based therapies | 2.00% | High | North America, Europe | High | Mid Term |
| Expanding clinical trials combining oncolytic viruses with immunotherapy accelerating treatment innovation | 1.90% | High | North America, Asia Pacific | Emerging | Long Term |
| Increasing government and institutional research funding supporting commercialization of virotherapy platforms | 1.60% | High | Europe, North America | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest position in the oncolytic virotherapy market in 2026, reflecting its advanced oncology infrastructure, strong research ecosystem, and growing adoption of innovative cancer treatment approaches. The region has a well-established clinical environment for developing and evaluating novel immuno-oncology therapies, while increasing interest in targeted treatment strategies is encouraging the exploration of virus-based approaches that can selectively attack tumor cells and stimulate immune responses. Strong investment in biotechnology research, specialized cancer centers, and advanced clinical capabilities supports continued development and adoption. Growing emphasis on personalized and immune-based cancer care further contributes to the region's market leadership.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, supported by expanding oncology care infrastructure, rising cancer treatment needs, and increasing investment in advanced biopharmaceutical research. Healthcare systems across the region are progressively adopting innovative therapeutic approaches as access to specialized cancer services improves. Greater participation in clinical research, development of biotechnology capabilities, and increasing collaboration across healthcare and research institutions are creating a stronger environment for oncolytic virotherapy. At the same time, rising awareness of immunotherapy and targeted cancer treatment is supporting demand for emerging therapeutic options, strengthening the region's growth potential.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Research FocusGermany emphasizes translational oncology programs that connect academic discoveries with commercial therapeutic development. German research institutions and biopharmaceutical companies are expanding partnerships to evaluate oncolytic virotherapy across multiple solid tumor indications.
France 🇫🇷
Academic Collaboration NetworkFrance supports oncolytic virotherapy through coordinated academic research and hospital-based oncology programs. French institutions are evaluating innovative viral therapies alongside established cancer treatments to broaden therapeutic options within clinical practice.
Italy 🇮🇹
Hospital Research ExpansionItaly is increasing participation in multicenter oncology studies that include investigational oncolytic virotherapy treatments. Italian healthcare institutions are focusing on improving patient access to innovative cancer therapies through collaborative clinical research initiatives.
Japan 🇯🇵
Precision Oncology IntegrationJapan is integrating oncolytic virotherapy into precision oncology initiatives supported by advanced molecular diagnostics. Japanese developers are exploring combination therapies with immune checkpoint inhibitors to improve treatment outcomes for selected patient populations.
South Korea 🇰🇷
Biotech Development PipelineSouth Korea is strengthening its biotechnology ecosystem with investments in viral vector technologies and cancer immunotherapy research. Local companies are advancing clinical development programs while collaborating with international partners to expand commercialization opportunities.
United States 🇺🇸
Clinical Innovation HubThe U.S. continues to prioritize advanced oncology research through extensive clinical trial activity and collaboration between biotechnology firms and cancer centers. Regulatory experience and investment in novel immunotherapies support broader development of oncolytic virotherapy platforms.
Segment Leadership and Growth Trends
Oncolytic Virotherapy Market Share (%), by Virus Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportVirus Type Segment Analysis: Genetically Engineered Oncolytic (Largest & Fastest-Growing Segment)
Genetically engineered oncolytic segment accounted for both the largest and fastest-growing share of the oncolytic virotherapy market in 2026, reflecting the growing importance of engineered viruses designed to selectively target and destroy cancer cells. Genetic modification can enhance viral tumor selectivity, improve therapeutic activity, and enable incorporation of mechanisms intended to stimulate antitumor immune responses. Continued advances in cancer biology and genetic engineering are supporting the development of increasingly sophisticated oncolytic therapies. Growing interest in targeted and immune-mediated cancer treatment is further strengthening the segment's market position.
Application Segment Analysis: Melanoma (Largest Segment) vs Solid Tumors (Fastest-Growing Segment)
Melanoma segment held the largest share of the oncolytic virotherapy market in 2026, supported by the clinical relevance of oncolytic approaches in treating melanoma and the segment's role in the development and adoption of virus-based cancer therapies. Melanoma provides an important application area for therapies designed to selectively target malignant cells while stimulating immune responses against tumors. Continued innovation in cancer immunotherapy and growing interest in treatment approaches that can complement existing therapeutic strategies are supporting demand in this application. The established clinical focus on melanoma therefore continues to contribute to its leading position.
Solid tumors are the fastest-growing application segment, driven by expanding research into the use of oncolytic viruses across a broader range of difficult-to-treat cancers. Solid tumors represent a substantial therapeutic opportunity because engineered viruses can potentially be designed to target tumor cells while activating localized and systemic immune responses. Increasing investment in innovative cancer therapies and advances in tumor-specific targeting are encouraging broader investigation of oncolytic virotherapy beyond established applications. The pursuit of more effective treatment options for diverse solid malignancies is consequently creating significant growth opportunities for this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Virus Type | Genetically Engineered Oncolytic, Oncolytic Wild-Type Viruses | Genetically Engineered Oncolytic | Genetically Engineered Oncolytic |
| Application | Solid Tumors, Melanoma | Melanoma | Solid Tumors |
| End-use | Hospitals, Specialty Clinics, Cancer Research Institutes | Hospitals | Specialty Clinics |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the oncolytic virotherapy market:
1. Amgen Inc. (United States)
2. Takara Bio Inc. (Japan)
3. Transgene SA (France)
4. Shanghai Sunway Biotech Co. Ltd. (China)
5. Pfizer Inc. (United States)
6. Calidi Biotherapeutics Inc. (United States)
7. Lokon Pharma AB (Sweden)
8. TILT Biotherapeutics Ltd. (Finland)
9. CG Oncology Inc. (United States)
The oncolytic virotherapy market is progressing through advanced immunotherapy research and targeted viral engineering approaches. Collaborative innovation networks are accelerating clinical development and trial expansion. New therapy introductions reflect growing focus on precision oncology solutions. Strengthened research ecosystems are enabling faster translation from laboratory innovation to clinical application.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Amgen Inc. (United States) | |||||||
| Takara Bio Inc. (Japan) | |||||||
| Transgene SA (France) | |||||||
| Shanghai Sunway Biotech Co. Ltd. (China) | |||||||
| Pfizer Inc. (United States) | |||||||
| Calidi Biotherapeutics Inc. (United States) | |||||||
| Lokon Pharma AB (Sweden) | |||||||
| TILT Biotherapeutics Ltd. (Finland) | |||||||
| CG Oncology Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Genelux Corporation | Jun-26 | Genelux Corporation initiated a Phase 1b/2 clinical study to evaluate the safety and anti-tumor activity of its proprietary Olvi-Vec oncolytic immunotherapy in patients with recurrent or refractory ovarian cancer. This progression into mid-stage clinical trials marks a significant operational step toward validating the efficacy of its virotherapy platform in complex, difficult-to-treat solid tumor segments. |
| SillaJen Inc. | Jun-26 | SillaJen Inc. announced the commencement of a Phase 3 study for its vaccinia virus-based immunotherapy, Pexa-Vec, in combination with sorafenib for advanced hepatocellular carcinoma. By advancing to late-stage pivotal testing, this initiative represents a major commitment to establishing a new standard-of-care regimen and demonstrates the commercial scalability of the company’s lead therapeutic candidate. |
| UroGen Pharma | Feb-26 | UroGen Pharma acquired key assets related to the oncolytic virus ICVB-1042 from IconOVir Bio, Inc. This strategic acquisition expands UroGen’s clinical pipeline, reflecting an industry-wide trend of consolidating high-potential virotherapy assets to address unmet needs in targeted cancer treatment and enhancing the company's competitive position in the immunotherapy space. |
| Calidi Biotherapeutics | Aug-25 | Calidi Biotherapeutics received FDA Fast Track designation for CLD-201, an investigational oncolytic virus therapy targeting soft tissue sarcoma. This regulatory milestone accelerates the clinical development pathway for the candidate, providing a streamlined framework for regulatory interaction and underscoring the therapy's potential to address significant medical gaps in aggressive oncology indications. |
| Imugene | Nov-24 | Imugene reported sustained complete response data in a patient with bile tract cancer from its Phase I MAST trial, with the patient remaining in remission for over two years. This long-term clinical outcome provides robust evidence supporting the durability and therapeutic potential of Imugene’s oncolytic virotherapy approach in addressing complex gastrointestinal malignancies. |
| Tomahawk Oncology | Jul-24 | Tomahawk Oncology entered an exclusive licensing agreement with the University of Houston to commercialize proprietary cancer therapeutic technology. This strategic partnership broadens the company’s oncology research portfolio, positioning it to integrate new virotherapy-relevant assets into its development pipeline and enhancing its long-term research and development capabilities in the cancer immunotherapy market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Oncolytic Virotherapy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Delivery Route | Intratumoral, Intravenous, Intraperitoneal, Other Routes |
| Treatment Regimen | Monotherapy, Combination Therapy with Immunotherapy, Combination Therapy with Chemotherapy, Combination Therapy with Targeted Therapy |
| Commercialization Status | Approved Therapies, Late-Stage Clinical Therapies, Early-Stage Clinical Therapies, Preclinical Therapies |
Oncolytic Virotherapy Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Development Pipeline Competitiveness Assessment |
|
| Cancer Center Adoption Readiness Analysis |
|
| Manufacturing and Viral Vector Capacity Landscape |
|
Need a different cut of the data?
Request Custom ResearchHow large is the oncolytic virotherapy market?
How is the oncolytic virotherapy industry projected to perform over the next decade?
How is the expansion of combination therapies with immunotherapy shaping adoption in the oncolytic virotherapy market?
Why is rising cancer burden accelerating investment in oncolytic virotherapy development programs?
Why do Genetically Engineered Oncolytic viruses dominate the oncolytic virotherapy market?
Why are Solid Tumors the fastest-growing application in the oncolytic virotherapy market?
What makes North America the leading region in the oncolytic virotherapy market?
Why is Asia Pacific emerging as the fastest-growing oncolytic virotherapy market?
Who holds a significant market share in the oncolytic virotherapy landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization